References
- Steinberg D. The cholesterol controversy is over. Why did it take so long?. Circulation 1989; 80: 1070–78
- Smith W CS, Kenicer M B, Davis A M, Evans A E, Yarnell J. Blood cholesterol: Is population screening warranted in the UK?. Lancet 1989; 1: 372–73
- Cutler J A, MacMahon S W, Furberg C D. Controlled clinical trials of drug treatment for hypertension. A review. Hypertension 1989; 13(Suppl I)I-36–I-44
- Muldoon M F, Manuck S B, Matthews K A. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. Br Med J 1990; 301: 309–14
- Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916–24
- Rossouw J E, Rifkind B M. Lowering cholesterol concentrations and mortality [Letter]. Br Med J 1990; 301: 814–15
- Joint Statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990; 81: 1721–33
- McCormick J, Skrabanek P. Coronary heart disease is not preventable by population interventions. Lancet 1988; 2: 839–41
- Corday E, Ryden L. Why some physicians have concerns about the cholesterol awareness program. JACC 1989; 13: 497–502
- Brett A S. Treating hypercholesterolemia How should practicing physicians interpret the published data for patients?. N Engl J Med 1989; 321: 676–80
- Isles C G, Hole D J, Gillis C R, Hawthorn V M, Lever A F. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. Br Med J 1989; 298: 920–24
- Oliver M F. Reducing cholesterol does not reduce mortality. JACC 1988; 12: 814–17
- Winawer S J, Flehinger B J, Buchalter J, Herbert E, Shike M. Declining serum cholesterol levels prior to diagnosis of colon cancer. A time-trend, case control study. JAMA 1990; 263: 2083–85
- Frick M H, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45
- Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. JAMA 1984; 251: 351–64
- Wysowski D K, Gross T P. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990; 150: 2169–72
- Kaplan J R, Manuck S B. The effects of fat and cholesterol on aggressive behavior in monkeys [Abstract]. Psychosomatic Med 1990; 52: 226
- Taylor W C, Pass T, Shepard D S, Komaroff A L. Cholesterol reduction and life expectancy: A model incorporating multiple risk factors. Ann Intern Med 1987; 106: 605–14
- Hay J W, Wittels E H, Gotto A M, Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991; 67: 789–96
- Schulman K A, Kinosian B, Jacobson T A, Glick H, Willian M K, Koffer H, Eisenberg J M. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025–33
- Goldman L, Weinstein M C, Goldman P A, Williams L W. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145–51
- Anonymous. Low cholesterol and increased risk [Editorial]. Lancet 1989; 1: 1423–6
- Wysowski D K, Kennedy D L, Gross T P. Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988. JAMA 1990; 263: 2185–88